Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.